[{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"load-required-r-packages","dir":"Articles","previous_headings":"","what":"Load required R packages","title":"A4 and LEARN Screening and Baseline","text":"","code":"library(tidyverse) library(arsenal) library(A4LEARN)"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"prepare-data","dir":"Articles","previous_headings":"","what":"Prepare data","title":"A4 and LEARN Screening and Baseline","text":"Rescreens Participants re-screened may appear data twice different BIDs time. A4LEARN::SUBJINFO derived dataset indicates participants re-screens, re-screen BIDs mapped . code also accounts set removal duplicate appearances. Gather Amyloid PET data Amyloid PET quantitative data (A4LEARN::imaging_SUVR_amyloid) long format one row per region. use tidyr::pivot_wider transform wide format one column per region. Baseline PACC Prepare data table","code":"rescreens <- A4LEARN::SUBJINFO %>%   filter(!is.na(PREVBID)) %>%   rename(BID1 = PREVBID, BID2 = BID) %>%   select(BID1, BID2) pet <- A4LEARN::imaging_SUVR_amyloid %>%    filter(brain_region != '' & VISCODE == 2) %>%   pivot_wider(id_cols='BID', names_from=brain_region, values_from=suvr_cer) %>%   left_join(A4LEARN::imaging_PET_VA, by='BID') %>%   left_join(rescreens, by=c('BID' = 'BID1')) %>%    mutate( # update PET BIDs to second BID if necessary     BID = case_when(       !is.na(BID2) ~ BID2,       TRUE ~ BID)) %>%   arrange(BID, BID2) %>%   filter(!duplicated(BID, fromLast = TRUE)) %>%   select(-BID2) pacc_bl <- A4LEARN::PACC %>%    filter(VISCODE == 6) %>%   select(BID, PACC.raw, MMSCORE, LDELTOTAL, DIGITTOTAL, FCTOTAL96) dd <- A4LEARN::SUBJINFO %>% select(BID, APOEGN) %>%   left_join(A4LEARN::ptdemog, by='BID') %>%   left_join(pet, by=c('SUBSTUDY','BID')) %>%   left_join(pacc_bl, by=c('BID')) %>%   # remove first appearance of rescreens:   filter(!BID %in% rescreens$BID1) %>%    rename(`A4 amyloid eligibility` = overall_score) %>%   rename(     `Age at screening (yrs)` = PTAGE,     `APOE genotype` = APOEGN,      `Education (yrs)` = PTEDUCAT,      `Amyloid PET SUVr^b^` = Composite_Summary,     Sex = PTGENDER,     Ethnicity = PTETHNIC,     `Marital status` = PTMARRY,     `Participant retired` = PTNOTRT,     PACC = PACC.raw,      MMSE = MMSCORE,      `Logical memory delay` = LDELTOTAL,      `Digit symbol` = DIGITTOTAL,      `FCSRT (2xFree + Cued)` = FCTOTAL96,     `A4 amyloid eligibility^b^` = `A4 amyloid eligibility`) %>%    # rename values and fields for footnote setup in summary table   mutate(SUBSTUDY = factor(SUBSTUDY, levels = c('A4', 'LEARN'),     labels = c('A4^a^' , 'LEARN')))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"characteristics-by-screening-amyloid-pet-status","dir":"Articles","previous_headings":"","what":"Characteristics by screening amyloid PET status","title":"A4 and LEARN Screening and Baseline","text":"Characteristics underwent screening amyloid PET comparison Elevated (Aβ−) Elevated Amyloid (Aβ+) groups","code":"tableby(`A4 amyloid eligibility^b^` ~ .,   data = dd %>%     filter(!is.na(`Amyloid PET SUVr^b^`)) %>%     select(`A4 amyloid eligibility^b^`, `Age at screening (yrs)`,        `Education (yrs)`, `APOE genotype`, `Amyloid PET SUVr^b^`,        Sex, Ethnicity, `Marital status`, `Participant retired`, PACC, MMSE,        `Logical memory delay`, `Digit symbol`, `FCSRT (2xFree + Cued)`),    digits = 2) %>%   summary(title = \"Characteristics of all who underwent screening amyloid PET with comparison of Not Elevated (Aβ−) and Elevated Amyloid (Aβ+) groups\")"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"characteristics-by-a4-vs-learn","dir":"Articles","previous_headings":"","what":"Characteristics by A4 vs LEARN","title":"A4 and LEARN Screening and Baseline","text":"Baseline characteristics A4-randomizeda LEARN-enrolled cohorts A4-randomized cohort (n=1169) includes participants addition modified intention--treat population (mITT n=1147) reported A4 trial (Sperling et al. 2023). modified intention--treat population population reported A4 trial results include received least one dose solanezumab placebo underwent assessment primary end point. Please refer vignette(topic = 'A4-Primary-Results') file code reproduce baseline characteristics primary findings A4 study.b Refer A4 Amyloid PET Eligibility Methods PDF document (vignette(topic = 'imaging_PET_VA_methods')) regarding amyloid-related measures, eligibility determination process modifications made SUVR algorithm.","code":"tableby(SUBSTUDY ~ .,   data = dd %>%     filter(!SUBSTUDY %in% 'SF') %>% # excluding screen-fails     select(SUBSTUDY, `A4 amyloid eligibility^b^`, `Age at screening (yrs)`,        `Education (yrs)`, `APOE genotype`, `Amyloid PET SUVr^b^`, Sex, Ethnicity,       `Marital status`, `Participant retired`, PACC, MMSE,        `Logical memory delay`, `Digit symbol`, `FCSRT (2xFree + Cued)`),    digits = 2) %>%   summary(title = \"Baseline characteristics of A4-randomized^a^ and LEARN-enrolled cohorts\")"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"load-required-r-packages","dir":"Articles","previous_headings":"","what":"Load required R packages","title":"A4 Primary Results","text":"","code":"library(tidyverse) library(arsenal) library(kableExtra) library(nlme) library(emmeans) library(splines) library(clubSandwich) library(A4LEARN)  formatp <- function(x) case_when(   x < 0.001 ~ \"p<0.001\",   x > 0.01 ~ Hmisc::format.pval(x, digits=2, eps=0.01, nsmall=2),   TRUE ~ Hmisc::format.pval(x, digits=3, eps=0.001, nsmall=3))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"organize-data","dir":"Articles","previous_headings":"","what":"Organize data","title":"A4 Primary Results","text":"","code":"# Outcomes collected at Visit 1 V1OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"001\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  # Outcomes collected at Visit 6 V6OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"006\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  SUBJINFO <- A4LEARN::SUBJINFO %>%   left_join(V6OUTCOME, by = \"BID\") %>%   left_join(V1OUTCOME %>%       select(BID, CDRSB, CFITOTAL, CFISP, CFIPT, ADLPQPT, ADLPQSP),      by = \"BID\")  # Filter A4LEARN::ADQS for PACC collected in the blinded phases among mITT population ADQS_PACC <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"006\") %>%   dplyr::filter(QSTESTCD == \"PACC\") %>%   rename(PACC = QSSTRESN) %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSVERSION, PACC) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit()"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"baseline-characteristics-of-the-a4-trial","dir":"Articles","previous_headings":"","what":"Baseline characteristics of the A4 trial","title":"A4 Primary Results","text":"Characteristics A4 participants randomized treatment group (Modified Intention--Treat Population received least one dose solanezumab placebo underwent assessment primary end point).","code":"A4labels <- list(TX = \"Treatment group\", AGEYR = \"Age (y)\",    EDCCNTU = \"Education (y)\", SUVRCER = \"FBP SUVr\", AMYLCENT = \"FBP Centiloid\",    LMIIa = \"LM Delayed Recall\",  MMSE = \"MMSE\",    CFITOTAL = \"CFI Combined\", ADLPQSP = \"ADL Partner\", CDRSB = \"CDR-SB\",   SEX = \"Sex\", RACE = \"Racial categories\", ETHNIC = \"Ethnicity\",    MARITAL = \"Marital Status\",  WRKRET = \"Retirement Status\",    APOEGNPRSNFLG = \"APOE e4\", APOEGN = \"APOE Genotype\")  table1 <- tableby(TX ~ AGEYR + EDCCNTU + SEX + RACE + ETHNIC + MARITAL + WRKRET +      SUVRCER + AMYLCENT + chisq(APOEGN) + chisq(APOEGNPRSNFLG) +      PACC + LMIIa + MMSE + CFITOTAL + ADLPQSP + CDRSB,    data = SUBJINFO %>% dplyr::filter(MITTFL== 1),    control = tableby.control(test=TRUE,     stats.labels = list(Nmiss = \"Missing\")))  summary(table1, labelTranslations = A4labels, digits = 1,   title = \"Characteristics of the A4 participants by randomized treatment group (Modified Intention-to-Treat Population of those who received at least one dose of solanezumab or placebo and underwent assessment for the primary end point).\")"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"primary-analyis-of-the-pacc","dir":"Articles","previous_headings":"","what":"Primary analyis of the PACC","title":"A4 Primary Results","text":"Preclinical Alzheimer Cognitive Composite (PACC, Donohue et al. (2014)) data modeled using natural cubic splines described Donohue et al. (2023). fixed effects included following terms: () spline basis expansion terms (two terms), (ii) spline basis expansion terms--treatment interaction (two terms), (iii) PACC test version administered, (iv) baseline age, (v) education, (vi) APOE4 Carrier Status (yes/), (vii) baseline florbetapir cortical SUVr. model constrained allow difference treatment group means baseline. following variance-covariance structures assumed sequence model converged: () heterogeneous unstructured, (ii) heterogeneous Toeplitz, (iii) heterogeneous autoregressive order 1, (iv) heterogeneous compound symmetry, (v) compound symmetry. first structure, heterogeneous unstructured, converge. fit second, heterogeneous Toeplitz, converge. Spaghetti plot PACC data time treatment group. Mean PACC change baseline week 240 treatment group estimated spline model. Mean PACC group change baseline week 240 treatment group estimated spline model. Mean PACC per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"ggplot(ADQS_PACC, aes(x=ADURW, y=PACC, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.2)) +   xlab(\"Weeks since Randomization\") +   scale_x_continuous(breaks = seq(0, max(ADQS_PACC$ADURW), by = 24)) # Spline basis expansion functions # CAUTION: these function depend on the ADQS_PACC data frame object in the  # global environment. If ADQS_PACC changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: pacc_fit <- gls(PACC ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER + QSVERSION,   data = ADQS_PACC,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 10)) ref_grid(pacc_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(pacc_fit,    at = list(ADURW = 240, TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(pacc_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean PACC with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.2))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"primary-analyis-of-the-cfi","dir":"Articles","previous_headings":"","what":"Primary analyis of the CFI","title":"A4 Primary Results","text":"Spaghetti plot CFI data time treatment group. Mean CFI change baseline week 240 treatment group estimated spline model. Mean CFI group change baseline week 240 treatment group estimated spline model. Mean CFI per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"# Filter A4LEARN::ADQS for CFITOTAL collected in the blinded phases among mITT population ADQS_CFI <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"001\") %>%   dplyr::filter(QSTESTCD == \"CFITOTAL\") %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSSTRESN) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit() ggplot(ADQS_CFI, aes(x=ADURW, y=QSSTRESN, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.9)) +   xlab(\"Weeks since Randomization\") +   ylab(\"CFI Participant and Partner\") scale_x_continuous(breaks = seq(0, max(ADQS_CFI$ADURW), by = 24)) <ScaleContinuousPosition>  Range:    Limits:    0 --    1 # Spline basis expansion functions # CAUTION: these function depend on the ADQS_CFI data frame object in the  # global environment. If ADQS_CFI changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: cfi_fit <- gls(QSSTRESN ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER,   data = ADQS_CFI,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 5)) ref_grid(cfi_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(cfi_fit,    at = list(ADURW = 240, TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(cfi_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean CFI with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.9))"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"research-in-context","dir":"Articles","previous_headings":"","what":"Research in Context","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Evidence study searched PubMed, MEDLINE, Google Scholar articles published January 1, 2000, December 31, 2025, using terms “preclinical Alzheimer’s disease,” “cognitive decline,” “latent class.” Previous studies identified patterns cognitive decline aging populations, limited understanding predictive value recently developed biomarkers Alzheimer’s pathology, found studies examining impact secondary prevention trial design. Added value study study first apply latent class analysis data A4 LEARN studies, identifying distinct classes cognitive decline individuals risk Alzheimer’s disease. findings reveal significant heterogeneity cognitive trajectories, suggesting preclinical Alzheimer’s disease uniform process. insights inform personalized intervention strategies improve design future clinical trials. Implications available evidence results underscore importance considering individual variability cognitive decline developing testing interventions preclinical Alzheimer’s disease. Recognizing diverse patterns cognitive decline can enhance precision clinical trial designs lead effective, tailored therapeutic approaches. Future research focus validating findings larger, diverse cohorts exploring underlying mechanisms driving observed heterogeneity.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"introduction","dir":"Articles","previous_headings":"","what":"Introduction","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Elevated levels brain amyloid cognitively unimpaired older adults associated subsequent cognitive decline increased risk clinical progression.1–5 Anti-Amyloid Treatment Asymptomatic Alzheimer’s Disease (A4) Study, randomized trial solanezumab cognitively normal individuals elevated amyloid PET, demonstrated group-level decline cognitive composite treatment benefit.2 Follow-analyses A4 companion observational study amyloid-negative individuals, Longitudinal Evaluation Amyloid Risk Neurodegeneration (LEARN), confirmed higher baseline amyloid PET plasma phosphorylated tau (P‐tau217) levels associated faster cognitive decline increased functional progression.5 Despite consistent group-level associations, cognitive trajectories among amyloid-positive individuals remain highly variable. Conventional longitudinal models assume individual cognitive trajectories randomly scattered single mean trend given covariate values, potentially obscuring meaningful heterogeneity. better characterize heterogeneity, applied Latent Class Mixed-Effects Model (LCMM)6 A4 LEARN data. approach identifies unobserved subgroups participants distinct longitudinal patterns change allows evaluation baseline biomarkers demographic factors predictors class membership. Latent class growth model approaches applied several times literature identify distinct classes late-life cognitive trajectories. systematic review Wu et al.7 identified 37 investigations consistently identified three classes: stable, slow decline, fast decline. However, many papers lacked recently developed biomarkers Alzheimer’s pathology. One exception study Teipel et al.8 included amyloid PET predictor cohort N=265N=265 individuals followed two years. Villeneuve et al.9 identified latent classes Amsterdam Instrumental-Activities--Daily-Living questionnaire using amyloid PET FDG PET N=289 participants three years. , consider latent classes cognition predicted APOE genotype, amyloid PET, P‐tau217, hippocampal atrophy, tau PET cohort N=1,629N=1,629 individuals followed seven years A4 LEARN. Furthermore, explore practical implications classification algorithms clinical trials.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"methods","dir":"Articles","previous_headings":"","what":"Methods","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"A4 LEARN studies previously described2,5, briefly summarize key elements. A4 Study multicenter, randomized, double-blind, placebo-controlled secondary prevention trial enrolling cognitively unimpaired older adults aged 65–85 years elevated brain amyloid florbetapir PET. Participants recruited 67 sites United States, Canada, Australia, Japan underwent standardized screening, baseline clinical assessment, biomarker acquisition, neuropsychological testing. eligibility confirmation, participants randomized receive solanezumab placebo assessed longitudinally regular cognitive evaluations, safety monitoring, follow-imaging fluid biomarker collection per protocol. LEARN study conducted parallel observational cohort enrolling individuals met A4 screening criteria except amyloid PET positivity. LEARN participants completed identical clinical cognitive assessments, allowing direct comparison trajectories amyloid-positive amyloid-negative individuals. studies followed harmonized procedures data collection, visit scheduling, quality control ensure comparability longitudinal outcomes. participants studies provided written informed consent, study protocols approved institutional review boards ethics committees participating site. Latent class mixed-effects models (LCMMs) extend traditional mixed-effects models identifying unobserved subgroups, latent classes, individuals follow distinct longitudinal trajectories. context cognitive decline Alzheimer’s disease, LCMMs allow estimation population-level trends capturing individual variability uncovering hidden subpopulations may progress different rates. Analyses conducted using harmonized data A4 LEARN studies, accessed A4LEARN R data package (version 1.1.2025080810,11). package provides curated datasets metadata derived A4 LEARN clinical studies reproducible statistical analysis. Code reproduce results paper available A4LEARN GitHub repository12. dependent variable Box-Cox-transformed Preclinical Alzheimer Cognitive Composite (PACC)13 score visit. Box-Cox transformation parameter (λ\\lambda) selected maximize likelihood transformed data approximated normality. Time modeled continuous variable representing years since baseline. Natural cubic spline basis functions one, two three degrees freedom evaluated model nonlinear trajectories, boundary knots baseline maximum follow-time interior knots median tertiles observation time. choice degrees freedom number classes (also one, two, three) determined model fit criteria (Bayesian Information Criterion [BIC] Integrated Complete Likelihood [ICL]).14 model included class-specific spline-based time effects, well subject-specific random intercepts. effect baseline covariates shared across latent classes included: randomized solanezumab (1 active group, 0 placebo LEARN), plasma P-tau217 concentration, florbetapir cortical standardized uptake value ratio (SUVr), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC test stimulus version administered (alternated per study protocol). Plasma P-tau217 concentrations measured using immunoassay developed Eli Lilly reported arbitrary units per milliliter (U/mL), “U” denotes generic assay unit proportional signal intensity. Absolute calibration mass concentration (e.g., pg/mL) available. Hippocampal atrophy measures derived first residualizing respect intracranial volume, standardizing mean zero variance one (.e. z-scoring). LCMM includes two linked submodels. longitudinal submodel captures within-class trajectories cognitive change time. class set spline coefficients, allowing class-specific shapes decline. class membership submodel defines probability belonging latent class multinomial logistic function baseline covariates (includes covariates listed except spline terms PACC test version). secondary analysis, fit model subset participants baseline flortaucipir (tau) PET imaging. Tau PET summarized mean SUVr across eight cortical regions: entorhinal cortex, inferior temporal, inferior parietal, posterior cingulate, caudal middle frontal, middle temporal, superior parietal, frontal pole. composite measure included additional covariate longitudinal class membership submodels assess whether tau pathology improved prediction cognitive decline patterns latent class assignment. assess reliability potential predictive utility latent class membership model, examined posterior probabilities class assignment participant. High posterior probabilities indicate greater certainty latent class classification. summarized distributions across classes computed mean posterior probability within group index classification confidence. explore impact heterogeneity clinical trials preclinical Alzheimer’s disease, conducted power calculations estimate power hypothetical trials targeting latent classes cognitive decline among amyloid-positive participants. Effect size estimates derived longitudinal models using natural cubic splines applied Preclinical Alzheimer Cognitive Composite (PACC) scores.15 Separate models fit () stable class, (b) decliner classes, (c) reference group amyloid-negative stable individuals. models included fixed effects time (two degrees freedom), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, plasma P-tau217, florbetapir PET. Residuals assumed normally distributed unstructured covariance matrix. group, extracted mean PACC residual variance model two time points: 2 years 4 years, representing potential trial durations. estimates used compute power detect treatment effects. Power approximated using two-sample t-test calculations, assuming 500 participants per arm, attrition rates 10% 2 years 20% 4 years, two-sided alpha 0.05. evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.16 evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis17,18. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"conduct-of-the-a4-and-learn-studies","dir":"Articles","previous_headings":"","what":"Conduct of the A4 and LEARN Studies","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"A4 LEARN studies previously described2,5, briefly summarize key elements. A4 Study multicenter, randomized, double-blind, placebo-controlled secondary prevention trial enrolling cognitively unimpaired older adults aged 65–85 years elevated brain amyloid florbetapir PET. Participants recruited 67 sites United States, Canada, Australia, Japan underwent standardized screening, baseline clinical assessment, biomarker acquisition, neuropsychological testing. eligibility confirmation, participants randomized receive solanezumab placebo assessed longitudinally regular cognitive evaluations, safety monitoring, follow-imaging fluid biomarker collection per protocol. LEARN study conducted parallel observational cohort enrolling individuals met A4 screening criteria except amyloid PET positivity. LEARN participants completed identical clinical cognitive assessments, allowing direct comparison trajectories amyloid-positive amyloid-negative individuals. studies followed harmonized procedures data collection, visit scheduling, quality control ensure comparability longitudinal outcomes. participants studies provided written informed consent, study protocols approved institutional review boards ethics committees participating site.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"statistical-analysis","dir":"Articles","previous_headings":"","what":"Statistical Analysis","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Latent class mixed-effects models (LCMMs) extend traditional mixed-effects models identifying unobserved subgroups, latent classes, individuals follow distinct longitudinal trajectories. context cognitive decline Alzheimer’s disease, LCMMs allow estimation population-level trends capturing individual variability uncovering hidden subpopulations may progress different rates. Analyses conducted using harmonized data A4 LEARN studies, accessed A4LEARN R data package (version 1.1.2025080810,11). package provides curated datasets metadata derived A4 LEARN clinical studies reproducible statistical analysis. Code reproduce results paper available A4LEARN GitHub repository12. dependent variable Box-Cox-transformed Preclinical Alzheimer Cognitive Composite (PACC)13 score visit. Box-Cox transformation parameter (λ\\lambda) selected maximize likelihood transformed data approximated normality. Time modeled continuous variable representing years since baseline. Natural cubic spline basis functions one, two three degrees freedom evaluated model nonlinear trajectories, boundary knots baseline maximum follow-time interior knots median tertiles observation time. choice degrees freedom number classes (also one, two, three) determined model fit criteria (Bayesian Information Criterion [BIC] Integrated Complete Likelihood [ICL]).14 model included class-specific spline-based time effects, well subject-specific random intercepts. effect baseline covariates shared across latent classes included: randomized solanezumab (1 active group, 0 placebo LEARN), plasma P-tau217 concentration, florbetapir cortical standardized uptake value ratio (SUVr), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC test stimulus version administered (alternated per study protocol). Plasma P-tau217 concentrations measured using immunoassay developed Eli Lilly reported arbitrary units per milliliter (U/mL), “U” denotes generic assay unit proportional signal intensity. Absolute calibration mass concentration (e.g., pg/mL) available. Hippocampal atrophy measures derived first residualizing respect intracranial volume, standardizing mean zero variance one (.e. z-scoring). LCMM includes two linked submodels. longitudinal submodel captures within-class trajectories cognitive change time. class set spline coefficients, allowing class-specific shapes decline. class membership submodel defines probability belonging latent class multinomial logistic function baseline covariates (includes covariates listed except spline terms PACC test version). secondary analysis, fit model subset participants baseline flortaucipir (tau) PET imaging. Tau PET summarized mean SUVr across eight cortical regions: entorhinal cortex, inferior temporal, inferior parietal, posterior cingulate, caudal middle frontal, middle temporal, superior parietal, frontal pole. composite measure included additional covariate longitudinal class membership submodels assess whether tau pathology improved prediction cognitive decline patterns latent class assignment. assess reliability potential predictive utility latent class membership model, examined posterior probabilities class assignment participant. High posterior probabilities indicate greater certainty latent class classification. summarized distributions across classes computed mean posterior probability within group index classification confidence. explore impact heterogeneity clinical trials preclinical Alzheimer’s disease, conducted power calculations estimate power hypothetical trials targeting latent classes cognitive decline among amyloid-positive participants. Effect size estimates derived longitudinal models using natural cubic splines applied Preclinical Alzheimer Cognitive Composite (PACC) scores.15 Separate models fit () stable class, (b) decliner classes, (c) reference group amyloid-negative stable individuals. models included fixed effects time (two degrees freedom), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, plasma P-tau217, florbetapir PET. Residuals assumed normally distributed unstructured covariance matrix. group, extracted mean PACC residual variance model two time points: 2 years 4 years, representing potential trial durations. estimates used compute power detect treatment effects. Power approximated using two-sample t-test calculations, assuming 500 participants per arm, attrition rates 10% 2 years 20% 4 years, two-sided alpha 0.05. evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.16 evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis17,18. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"latent-class-mixed-effects-models","dir":"Articles","previous_headings":"Methods","what":"Latent Class Mixed-Effects Models","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Latent class mixed-effects models (LCMMs) extend traditional mixed-effects models identifying unobserved subgroups, latent classes, individuals follow distinct longitudinal trajectories. context cognitive decline Alzheimer’s disease, LCMMs allow estimation population-level trends capturing individual variability uncovering hidden subpopulations may progress different rates. Analyses conducted using harmonized data A4 LEARN studies, accessed A4LEARN R data package (version 1.1.2025080810,11). package provides curated datasets metadata derived A4 LEARN clinical studies reproducible statistical analysis. Code reproduce results paper available A4LEARN GitHub repository12. dependent variable Box-Cox-transformed Preclinical Alzheimer Cognitive Composite (PACC)13 score visit. Box-Cox transformation parameter (λ\\lambda) selected maximize likelihood transformed data approximated normality. Time modeled continuous variable representing years since baseline. Natural cubic spline basis functions one, two three degrees freedom evaluated model nonlinear trajectories, boundary knots baseline maximum follow-time interior knots median tertiles observation time. choice degrees freedom number classes (also one, two, three) determined model fit criteria (Bayesian Information Criterion [BIC] Integrated Complete Likelihood [ICL]).14 model included class-specific spline-based time effects, well subject-specific random intercepts. effect baseline covariates shared across latent classes included: randomized solanezumab (1 active group, 0 placebo LEARN), plasma P-tau217 concentration, florbetapir cortical standardized uptake value ratio (SUVr), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC test stimulus version administered (alternated per study protocol). Plasma P-tau217 concentrations measured using immunoassay developed Eli Lilly reported arbitrary units per milliliter (U/mL), “U” denotes generic assay unit proportional signal intensity. Absolute calibration mass concentration (e.g., pg/mL) available. Hippocampal atrophy measures derived first residualizing respect intracranial volume, standardizing mean zero variance one (.e. z-scoring). LCMM includes two linked submodels. longitudinal submodel captures within-class trajectories cognitive change time. class set spline coefficients, allowing class-specific shapes decline. class membership submodel defines probability belonging latent class multinomial logistic function baseline covariates (includes covariates listed except spline terms PACC test version). secondary analysis, fit model subset participants baseline flortaucipir (tau) PET imaging. Tau PET summarized mean SUVr across eight cortical regions: entorhinal cortex, inferior temporal, inferior parietal, posterior cingulate, caudal middle frontal, middle temporal, superior parietal, frontal pole. composite measure included additional covariate longitudinal class membership submodels assess whether tau pathology improved prediction cognitive decline patterns latent class assignment. assess reliability potential predictive utility latent class membership model, examined posterior probabilities class assignment participant. High posterior probabilities indicate greater certainty latent class classification. summarized distributions across classes computed mean posterior probability within group index classification confidence.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"power-analysis-for-latent-class-specific-trials","dir":"Articles","previous_headings":"Methods","what":"Power Analysis for Latent Class-Specific Trials","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"explore impact heterogeneity clinical trials preclinical Alzheimer’s disease, conducted power calculations estimate power hypothetical trials targeting latent classes cognitive decline among amyloid-positive participants. Effect size estimates derived longitudinal models using natural cubic splines applied Preclinical Alzheimer Cognitive Composite (PACC) scores.15 Separate models fit () stable class, (b) decliner classes, (c) reference group amyloid-negative stable individuals. models included fixed effects time (two degrees freedom), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, plasma P-tau217, florbetapir PET. Residuals assumed normally distributed unstructured covariance matrix. group, extracted mean PACC residual variance model two time points: 2 years 4 years, representing potential trial durations. estimates used compute power detect treatment effects. Power approximated using two-sample t-test calculations, assuming 500 participants per arm, attrition rates 10% 2 years 20% 4 years, two-sided alpha 0.05.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"ten-fold-cross-validation-of-latent-class-predictions","dir":"Articles","previous_headings":"Methods","what":"Ten-fold cross-validation of latent class predictions","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.16","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"regression-tree-analysis-for-latent-class-characterization","dir":"Articles","previous_headings":"Methods","what":"Regression Tree Analysis for Latent Class Characterization","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis17,18. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"results","dir":"Articles","previous_headings":"","what":"Results","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"total N=1,629N=1,629 participants included analytic sample base model (without tau PET), comprising N=1,110N=1,110 A4 Study N=519N=519 LEARN study. mean (standard deviation [SD]) age baseline 71.46 (4.69) years, 60.2% female. median follow-time 6.0 years (interquartile range 3.9 7.0). Baseline characteristics stratified latent class membership presented Table 1. total N=427N=427 individuals tau PET data submitted tau PET model. tau PET subset included N=372N=372 A4 Study N=55N=55 LEARN study. Baseline characteristics tau PET subset presented Supplementary Table S1. Table 1: Baseline Demographic, Clinical, Biomarker Characteristics Latent Class Cognitive Decline. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit. Figure 1: Individual mean PACC trajectories latent class. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM). line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Figure 2: Distribution baseline demographic biomarker variables latent class cognitive decline. Sina plots show distribution selected baseline variables among latent classes identified latent class mixed model (LCMM) Preclinical Alzheimer Cognitive Composite (PACC) trajectories: stable, slow decliner, fast decliner. Variables include age, baseline PACC score, plasma phosphorylated tau 217 (P-tau217), amyloid positron emission tomography (PET) standardized uptake value ratio (SUVr), tau PET SUVr (subset tau PET available), hippocampal atrophy (volume normalized intracranial volume). dot represents individual participant; box plots represent quartiles. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal. Individual base LCMM (excluding Tau PET) mean trajectories shown Figure 1. Model selection criteria identified model two degrees freedom three latent classes, labeled stable (77%), slow decliner (16%), fast decliner (7%). next best fitting model three classes three degrees freedom (Δ\\Delta BIC = 22.2, Δ\\Delta ICL = 22.2). best fitting Tau PET LCMM two degrees freedom three latent classes (Supplementary Figure S3) next best fitting model two classes two degrees freedom (Δ\\Delta BIC = 376.4, Δ\\Delta ICL = 336.9). two models largely agreed individual classifications. 7/427 (1.6%) individuals reclassified one model next, none fast decliners. Posterior class probabilities (Supplementary Figure S4) indicated good separation (mean posterior probability, 0.94), indicating model confidence class assignment. three classes significantly separated starting immediately baseline. base model, participants classified fast decliners started mean -0.98 (95% confidence interval [CI] -1.44 -0.52) PACC points declined mean -15.8 (95% CI -16.7 -15.0) six years. contrast stable individuals started mean 0.52 (95% CI 0.37 0.67) PACC points improved mean 1.16 (95% CI 1.00 1.31) six years. Slow decliners intermediate two classes starting mean -0.13 (95% CI -0.44 0.17) PACC points declining mean -4.74 (95% CI -5.22 -4.26). Clinical relevance PACC latent classes supported differences functional outcomes. proportion participants observed progress Clinical Dementia Rating (CDR) Global score increased monotonically across latent classes, lowest rate among stable individuals (22.8%) progressively higher rates among slow- (71.9%) fast-decliners (88.2%) (Table 1). However, discordance PACC latent class labels observed CDR progression common. CDR Global scores greater zero possible without indication memory issues, explains little discordance. Among CDR progressors, proportion individuals CDR Memory Box score zero 8.4% PACC stable individuals, 5.5% slow decliners, 4.8% fast decliners. distribution continuous baseline variables latent class shown Figure 2 Supplementary Figure S1 summarizes standardized coefficients 95% CIs components LCMM. Supplementary Figure S1 Panels C depicts odds ratios (ORs) class membership submodels base model tau PET model. Continuous predictors standardized ORs reflect change odds belonging fast- slow declining class compared stable class per one SD increase continuous baseline predictor. base model (Panel ), higher plasma P-tau217 levels (3.2, 95% CI 2.4 4.1), elevated amyloid PET centiloid (1.4, 95% CI 1.0 1.9), greater hippocampal atrophy scores (3.9, 95% CI 2.7 5.6) associated increased odds belonging faster-declining classes. Interestingly, P-tau217 hippocampal atrophy numerically stronger effects amyloid PET. Also interest, fast decliners numerically younger (mean 73.1 years, SD 4.7), average, slow decliners (mean 74.1 years, SD 5.2) increased age associated membership slow declining group (1.4, 95% CI 1.1 1.7) fast declining group (0.93, 95% CI 0.69 1.2). Tau PET model results largely similar, confidence intervals wider, likely due smaller available sample (N=427N=427 vs N=1,629N=1,629). Increased tau PET associated increased odds slow- (= 1.8, 95% CI 1.2 2.8) fast-declining groups (= 3.6, 95% CI 2.1 6.1). Supplementary Figure S1 Panels B D presents standardized coefficients longitudinal submodels, representing associations covariate PACC outcome. Higher PACC scores correspond better cognitive performance continuous variables standardized oriented positive coefficients indicate better performance. see females increased risk fast decliners (2.5, 95% CI 1.5 4.4), better PACC performance given class membership (0.30 PACC points, 95% CI 0.24 0.35). APOE ϵ4\\epsilon 4 carriage associated increased risk slow (1.9, 95% CI 1.3 2.8) fast (2.9, 95% CI 1.6 5.3) declining class versus stable class, negligible remaining effect PACC. Education effect class membership, associated better PACC performance (0.12 PACC points per SD education, 95% CI 0.095 0.15). Figure 3: Trends latent class-specific clinical trials. Mean trajectories estimated longitudinal models using natural cubic splines (two degrees freedom) applied Preclinical Alzheimer Cognitive Composite (PACC) scores () two decliner classes, (b) amyloid-positive stable participants, (c) reference group amyloid-negative stable individuals representing maximum possible treatment benefit. decliners, power calculations assume treatment effect equal 20% maximum possible benefit 2 4 years. amyloid-positive stable participants, power calculations assume treatment effect equal 100% maximum possible benefit 2 4 years. Dashed lines represent projected mean PACC scores treatment; crosses indicate time points used power calculations. Latent class-specific power analyses revealed marked differences cognitive trajectories variability across classes (see Supplementary Table S2). amyloid-negative stable group highest mean (SD) PACC scores time: +1.14 (2.11) 2 years +1.20 (2.25) 4 years. considered maximum possible treatment benefit. stable amyloid-positive group means +0.88 (2.19) 2 years +0.96 (2.34) 4 years. 500 participants per arm, trial amyloid-positive stable individuals 44% power 2 years 30% 4 years detect even 100% maximum benefit (0.26 PACC points 2 years 0.24 4 years). contrast, trial amyloid-positive declining individuals 93% power 2 years 98% 4 years detect just 20% maximum benefit (0.79 PACC points 2 years 1.40 4 years). findings suggest stable amyloid-positive individuals, although may greatest potential long-term benefit disease-modifying drug, contribute little statistical power preclinical Alzheimer’s disease trial detect effect PACC. Instead, power primarily driven declining individuals, represent minority amyloid-positive population. Enrolling large numbers stable individuals may dilute overall treatment effect reduce trial’s ability detect meaningful cognitive benefits. results underscore need account latent classes decline designing preclinical Alzheimer’s disease trials. overall cross-validated accuracy 0.80 (95% CI 0.79 0.82) base model 0.756 (95% CI 0.73 0.78) tau PET model. However, accuracy rate inflated large number stable individuals (1,257/1,629 = 77.2%), relatively easy model identify. AUPRCs base model 0.95, 0.41, 0.49 non-, slow-, fast decliners versus rest; 0.70 either slow- fast decliner vs stable (Supplementary Figure S5). AUPRCs tau PET model 0.92, 0.31, 0.56 non-, slow-, fast decliners versus rest; 0.71 either slow- fast decliner vs stable (Supplementary Figure S6). optimally-tuned classification tree without tau PET achieved mean balanced accuracy 0.63 (standard error 0.007) 10-fold cross-validation (Supplementary Figure S2). Variable importance analysis identified baseline P-tau217 (56.2%), baseline PACC (15.5%), amyloid PET (13.1%), hippocampal atrophy (10.0%) important; though amyloid PET included tree, likely due correlation P-tau217. tree structure revealed hierarchical decision process participants baseline P-tau217 < 0.29 classified stable individuals, though miss-classifies N=155N=155 decliners. P-tau217 ≥\\geq 0.29 parsed hippocampal atrophy, PACC, P-tau217. one leaf contains majority fast decliners, contains 1% initial sample. tree demonstrates relative importance utility predictors, also demonstrates high degree miss-classification (31.4%). Cross-validated balanced accuracy improved addition tau PET (mean 0.69, standard error 0.02; Supplementary Figure S7). Tau PET second largest variable importance (22.5%), P-tau217 (29.8%) hippocampal atrophy (17.4%). tree tau PET results larger proportion leaves majority fast decliners (8.5% versus 1% without tau PET). characterize biological differences among latent trajectory groups, compared longitudinal changes amyloid PET, plasma P-tau217, tau PET (medial temporal neocortical), hippocampal volume across four classes (Figure 4). expected, slow fast decliners showed rapid biomarker progression across modalities, consistent steeper cognitive decline. contrast, Aβ– stable individuals demonstrated minimal change time biomarkers, supporting classification biologically clinically stable. Notably, Aβ+ stable individuals, despite showing PACC trajectories closely resembled Aβ– stable individuals, exhibited clear evidence biomarker progression, including increasing amyloid burden, rising plasma PET tau signals, accelerating hippocampal atrophy. findings suggest many Aβ+ stable individuals may represent earlier stage preclinical disease transition declining classes extended follow-, highlighting temporal dissociation biomarker progression short-term cognitive change. Figure 4: Longitudinal biomarker trajectories PACC latent class. panel displays individual biomarker trajectories (light lines) estimated mean trajectory (bold black line) linear mixed-effects model random slopes natural cubic spline fixed effects (2 degrees freedom). Columns correspond Aβ– stable, Aβ+ stable, slow decliner, fast decliner. Rows represent five longitudinal biomarkers: amyloid PET (Centiloids), plasma P-tau217 (U/mL), medial temporal lobe (MTL) tau PET SUVR, neocortical tau PET SUVR, hippocampal volume. Aβ– Aβ+ stable individuals demonstrate similarly stable cognitive trajectories, Aβ+ stable individuals exhibit clear biomarker progression across amyloid, tau, neurodegeneration measures, suggesting many may earlier stage preclinical disease transition declining classes longer follow-.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"study-participants","dir":"Articles","previous_headings":"","what":"Study Participants","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"total N=1,629N=1,629 participants included analytic sample base model (without tau PET), comprising N=1,110N=1,110 A4 Study N=519N=519 LEARN study. mean (standard deviation [SD]) age baseline 71.46 (4.69) years, 60.2% female. median follow-time 6.0 years (interquartile range 3.9 7.0). Baseline characteristics stratified latent class membership presented Table 1. total N=427N=427 individuals tau PET data submitted tau PET model. tau PET subset included N=372N=372 A4 Study N=55N=55 LEARN study. Baseline characteristics tau PET subset presented Supplementary Table S1. Table 1: Baseline Demographic, Clinical, Biomarker Characteristics Latent Class Cognitive Decline. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"characterization-and-prediction-of-latent-classes","dir":"Articles","previous_headings":"","what":"Characterization and Prediction of Latent Classes","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Figure 1: Individual mean PACC trajectories latent class. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM). line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Figure 2: Distribution baseline demographic biomarker variables latent class cognitive decline. Sina plots show distribution selected baseline variables among latent classes identified latent class mixed model (LCMM) Preclinical Alzheimer Cognitive Composite (PACC) trajectories: stable, slow decliner, fast decliner. Variables include age, baseline PACC score, plasma phosphorylated tau 217 (P-tau217), amyloid positron emission tomography (PET) standardized uptake value ratio (SUVr), tau PET SUVr (subset tau PET available), hippocampal atrophy (volume normalized intracranial volume). dot represents individual participant; box plots represent quartiles. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal. Individual base LCMM (excluding Tau PET) mean trajectories shown Figure 1. Model selection criteria identified model two degrees freedom three latent classes, labeled stable (77%), slow decliner (16%), fast decliner (7%). next best fitting model three classes three degrees freedom (Δ\\Delta BIC = 22.2, Δ\\Delta ICL = 22.2). best fitting Tau PET LCMM two degrees freedom three latent classes (Supplementary Figure S3) next best fitting model two classes two degrees freedom (Δ\\Delta BIC = 376.4, Δ\\Delta ICL = 336.9). two models largely agreed individual classifications. 7/427 (1.6%) individuals reclassified one model next, none fast decliners. Posterior class probabilities (Supplementary Figure S4) indicated good separation (mean posterior probability, 0.94), indicating model confidence class assignment. three classes significantly separated starting immediately baseline. base model, participants classified fast decliners started mean -0.98 (95% confidence interval [CI] -1.44 -0.52) PACC points declined mean -15.8 (95% CI -16.7 -15.0) six years. contrast stable individuals started mean 0.52 (95% CI 0.37 0.67) PACC points improved mean 1.16 (95% CI 1.00 1.31) six years. Slow decliners intermediate two classes starting mean -0.13 (95% CI -0.44 0.17) PACC points declining mean -4.74 (95% CI -5.22 -4.26). Clinical relevance PACC latent classes supported differences functional outcomes. proportion participants observed progress Clinical Dementia Rating (CDR) Global score increased monotonically across latent classes, lowest rate among stable individuals (22.8%) progressively higher rates among slow- (71.9%) fast-decliners (88.2%) (Table 1). However, discordance PACC latent class labels observed CDR progression common. CDR Global scores greater zero possible without indication memory issues, explains little discordance. Among CDR progressors, proportion individuals CDR Memory Box score zero 8.4% PACC stable individuals, 5.5% slow decliners, 4.8% fast decliners. distribution continuous baseline variables latent class shown Figure 2 Supplementary Figure S1 summarizes standardized coefficients 95% CIs components LCMM. Supplementary Figure S1 Panels C depicts odds ratios (ORs) class membership submodels base model tau PET model. Continuous predictors standardized ORs reflect change odds belonging fast- slow declining class compared stable class per one SD increase continuous baseline predictor. base model (Panel ), higher plasma P-tau217 levels (3.2, 95% CI 2.4 4.1), elevated amyloid PET centiloid (1.4, 95% CI 1.0 1.9), greater hippocampal atrophy scores (3.9, 95% CI 2.7 5.6) associated increased odds belonging faster-declining classes. Interestingly, P-tau217 hippocampal atrophy numerically stronger effects amyloid PET. Also interest, fast decliners numerically younger (mean 73.1 years, SD 4.7), average, slow decliners (mean 74.1 years, SD 5.2) increased age associated membership slow declining group (1.4, 95% CI 1.1 1.7) fast declining group (0.93, 95% CI 0.69 1.2). Tau PET model results largely similar, confidence intervals wider, likely due smaller available sample (N=427N=427 vs N=1,629N=1,629). Increased tau PET associated increased odds slow- (= 1.8, 95% CI 1.2 2.8) fast-declining groups (= 3.6, 95% CI 2.1 6.1). Supplementary Figure S1 Panels B D presents standardized coefficients longitudinal submodels, representing associations covariate PACC outcome. Higher PACC scores correspond better cognitive performance continuous variables standardized oriented positive coefficients indicate better performance. see females increased risk fast decliners (2.5, 95% CI 1.5 4.4), better PACC performance given class membership (0.30 PACC points, 95% CI 0.24 0.35). APOE ϵ4\\epsilon 4 carriage associated increased risk slow (1.9, 95% CI 1.3 2.8) fast (2.9, 95% CI 1.6 5.3) declining class versus stable class, negligible remaining effect PACC. Education effect class membership, associated better PACC performance (0.12 PACC points per SD education, 95% CI 0.095 0.15).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"power-analysis-for-latent-class-specific-trials-1","dir":"Articles","previous_headings":"","what":"Power Analysis for Latent Class-Specific Trials","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Figure 3: Trends latent class-specific clinical trials. Mean trajectories estimated longitudinal models using natural cubic splines (two degrees freedom) applied Preclinical Alzheimer Cognitive Composite (PACC) scores () two decliner classes, (b) amyloid-positive stable participants, (c) reference group amyloid-negative stable individuals representing maximum possible treatment benefit. decliners, power calculations assume treatment effect equal 20% maximum possible benefit 2 4 years. amyloid-positive stable participants, power calculations assume treatment effect equal 100% maximum possible benefit 2 4 years. Dashed lines represent projected mean PACC scores treatment; crosses indicate time points used power calculations. Latent class-specific power analyses revealed marked differences cognitive trajectories variability across classes (see Supplementary Table S2). amyloid-negative stable group highest mean (SD) PACC scores time: +1.14 (2.11) 2 years +1.20 (2.25) 4 years. considered maximum possible treatment benefit. stable amyloid-positive group means +0.88 (2.19) 2 years +0.96 (2.34) 4 years. 500 participants per arm, trial amyloid-positive stable individuals 44% power 2 years 30% 4 years detect even 100% maximum benefit (0.26 PACC points 2 years 0.24 4 years). contrast, trial amyloid-positive declining individuals 93% power 2 years 98% 4 years detect just 20% maximum benefit (0.79 PACC points 2 years 1.40 4 years). findings suggest stable amyloid-positive individuals, although may greatest potential long-term benefit disease-modifying drug, contribute little statistical power preclinical Alzheimer’s disease trial detect effect PACC. Instead, power primarily driven declining individuals, represent minority amyloid-positive population. Enrolling large numbers stable individuals may dilute overall treatment effect reduce trial’s ability detect meaningful cognitive benefits. results underscore need account latent classes decline designing preclinical Alzheimer’s disease trials.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"predictive-performance-and-cross-validation","dir":"Articles","previous_headings":"","what":"Predictive Performance and Cross-Validation","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"overall cross-validated accuracy 0.80 (95% CI 0.79 0.82) base model 0.756 (95% CI 0.73 0.78) tau PET model. However, accuracy rate inflated large number stable individuals (1,257/1,629 = 77.2%), relatively easy model identify. AUPRCs base model 0.95, 0.41, 0.49 non-, slow-, fast decliners versus rest; 0.70 either slow- fast decliner vs stable (Supplementary Figure S5). AUPRCs tau PET model 0.92, 0.31, 0.56 non-, slow-, fast decliners versus rest; 0.71 either slow- fast decliner vs stable (Supplementary Figure S6).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"post-hoc-regression-tree","dir":"Articles","previous_headings":"","what":"Post-hoc Regression Tree","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"optimally-tuned classification tree without tau PET achieved mean balanced accuracy 0.63 (standard error 0.007) 10-fold cross-validation (Supplementary Figure S2). Variable importance analysis identified baseline P-tau217 (56.2%), baseline PACC (15.5%), amyloid PET (13.1%), hippocampal atrophy (10.0%) important; though amyloid PET included tree, likely due correlation P-tau217. tree structure revealed hierarchical decision process participants baseline P-tau217 < 0.29 classified stable individuals, though miss-classifies N=155N=155 decliners. P-tau217 ≥\\geq 0.29 parsed hippocampal atrophy, PACC, P-tau217. one leaf contains majority fast decliners, contains 1% initial sample. tree demonstrates relative importance utility predictors, also demonstrates high degree miss-classification (31.4%). Cross-validated balanced accuracy improved addition tau PET (mean 0.69, standard error 0.02; Supplementary Figure S7). Tau PET second largest variable importance (22.5%), P-tau217 (29.8%) hippocampal atrophy (17.4%). tree tau PET results larger proportion leaves majority fast decliners (8.5% versus 1% without tau PET).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"longitudinal-biomarker-progression-across-latent-classes","dir":"Articles","previous_headings":"","what":"Longitudinal Biomarker Progression Across Latent Classes","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"characterize biological differences among latent trajectory groups, compared longitudinal changes amyloid PET, plasma P-tau217, tau PET (medial temporal neocortical), hippocampal volume across four classes (Figure 4). expected, slow fast decliners showed rapid biomarker progression across modalities, consistent steeper cognitive decline. contrast, Aβ– stable individuals demonstrated minimal change time biomarkers, supporting classification biologically clinically stable. Notably, Aβ+ stable individuals, despite showing PACC trajectories closely resembled Aβ– stable individuals, exhibited clear evidence biomarker progression, including increasing amyloid burden, rising plasma PET tau signals, accelerating hippocampal atrophy. findings suggest many Aβ+ stable individuals may represent earlier stage preclinical disease transition declining classes extended follow-, highlighting temporal dissociation biomarker progression short-term cognitive change. Figure 4: Longitudinal biomarker trajectories PACC latent class. panel displays individual biomarker trajectories (light lines) estimated mean trajectory (bold black line) linear mixed-effects model random slopes natural cubic spline fixed effects (2 degrees freedom). Columns correspond Aβ– stable, Aβ+ stable, slow decliner, fast decliner. Rows represent five longitudinal biomarkers: amyloid PET (Centiloids), plasma P-tau217 (U/mL), medial temporal lobe (MTL) tau PET SUVR, neocortical tau PET SUVR, hippocampal volume. Aβ– Aβ+ stable individuals demonstrate similarly stable cognitive trajectories, Aβ+ stable individuals exhibit clear biomarker progression across amyloid, tau, neurodegeneration measures, suggesting many may earlier stage preclinical disease transition declining classes longer follow-.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"discussion","dir":"Articles","previous_headings":"","what":"Discussion","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"latent class mixed-model analysis cognitively unimpaired older adults, identified distinct trajectories PACC performance evaluated extent plasma imaging biomarkers prospectively distinguished individuals remained cognitively stable showed slow rapid decline. Several findings highlight challenges prognostic modeling preclinical stage Alzheimer disease direct implications secondary prevention trial design. Although plasma P-tau217 amyloid PET associated latent class membership, neither biomarker alone, combination, achieved high accuracy predicting cognitive decline. key observation high frequency cognitive stability among amyloid-positive participants. shown Table 1, 776 1,110 amyloid-positive A4 participants (69.9%) classified stable individuals, indicating substantial amyloid burden necessarily translate measurable cognitive change timescales typical prevention trials. However, consistent pre-symptomatic phase disease believed last long 15 years. Compared 30.1% amyloid-positive individuals classified decliners, small minority amyloid-negative LEARN participants classified decliners. Thirty-eight 519 (7.3%) amyloid-negative individuals classified slow fast decliners, suggesting causes decline may reflect non–AD processes, early AD pathology PET detection thresholds baseline accumulated 5 year period, cognitive measurement variability. findings reinforce amyloid positivity, necessary defining AD pathophysiologic continuum, insufficient standalone predictor short- intermediate-term cognitive decline. Plasma P-tau217 demonstrated stronger prognostic associations amyloid PET, consistent biomarker models positioning tau abnormalities closer symptom onset. observation aligns prior reports, showing improved prognostic accuracy plasma tau markers.5 However, classification tree analyses indicated single P-tau217 threshold meaningfully enriched decliners without simultaneously excluding many true decliners, underscoring limitations threshold-based enrichment strategies. Tau PET provided incremental predictive value beyond plasma P-tau217 amyloid PET, although gains modest. tau PET captures later-stage pathologic changes, results biologically plausible. Nevertheless, logistical financial limitations tau PET constrain feasibility routine screening tool large-scale prevention trials. Participant Selection. amyloid-positive individuals remain cognitively stable, eligibility based solely amyloid positivity enroll many stable participants, reducing power cognitive endpoints. Plasma P-tau217 may improve enrichment reliably isolate decliners. complex multimodal strategies repeated biomarker assessments may needed adequate prognostic discrimination. Designing Trials Heterogeneous Cohorts. Traditional power calculations assume homogeneous population uniform treatment effect size, overlooking substantial heterogeneity cognitive trajectories. Fast decliners may show larger measurable effects often represent individuals along disease continuum exhibit greater variability, stable individuals pose different challenge. stability limits detectable cognitive benefit even biological effects occur, requiring treatments produce gains beyond natural improvement. analysis shows variability across classes directly influences minimum detectable effect sizes, meaning single-effect-size assumptions risk underpowered studies inefficient resource allocation. realistic simulation-based approaches incorporate class-specific trajectories differential treatment effects can improve trial design informing enrichment strategies, optimizing sample sizes, aligning outcomes subgroup trajectories. Added Value Tau PET. Tau PET provided additional predictive information incremental value must weighed feasibility. Tau-PET-based staging may help identify individuals closer clinical transition, though widespread implementation prevention trials remains challenging. Outcome Selection. Limited cognitive change stable individuals raises questions sensitivity traditional cognitive outcomes early stage. Digital measures learning curves biological endpoints plasma tau PET may offer responsive markers treatment effect serve secondary exploratory outcomes. Given evidence tau PET correlates strongly cognitive decline amyloid biomarkers, longitudinal tau PET plasma P-tau217 may useful monitoring treatment response detecting early trajectory divergence. Future work applying latent class trajectory models biomarker data may clarify whether biomarker-defined progressors can identified earlier reliably cognitive progressors. Early Intervention. Anti-amyloid therapies show greater benefit symptomatic individuals less tau pathology, supporting theory earlier intervention yields greater benefit. However, presymptomatic decline unfolds gradually decade , trials starting early may struggle demonstrate cognitive benefit within feasible windows. Refining validating sensitive digital biomarker-based endpoints essential advancing preclinical therapy development. Reliable measures target engagement disease progression improve enrichment, increase power, enable detection treatment effects even among cognitively stable participants. summary, data-driven cognitive trajectories among initially unimpaired older adults exhibited substantial heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective predicting decline time frame prevention trial. limitations highlight need improved prognostic tools, potentially incorporating longitudinal biomarker dynamics, multimodal risk models, digital assessments. , secondary prevention trials must account substantial heterogeneity cognitive trajectories planning enrollment, power calculations, trial simulations, analytic strategies. study several strengths. leveraged large, deeply phenotyped cohort cognitively unimpaired older adults longitudinal cognitive assessments harmonized biomarker data, using A4LEARN R package standardize reproducibly analyze data across A4 LEARN cohorts. latent class mixed-model approach allowed us identify data-driven cognitive trajectories rather relying predefined thresholds single-outcome definitions decline. inclusion plasma P-tau217, amyloid PET, , within subset, tau PET enabled evaluation multiple biomarkers spanning distinct phases Alzheimer disease pathophysiology. study also limitations. First, although latent class methods improve characterization heterogeneity, class assignments probabilistic sensitive model specification. Second, follow-duration, substantial, may still insufficient capture long-term cognitive change among stable individuals. Third, tau PET available subset, limiting statistical power comparisons involving biomarker potentially reducing generalizability. Fourth, although examined broad panel covariates, unmeasured factors, including comorbidities, lifestyle variables, scanner-related differences, may influence biomarker levels cognitive outcomes. Finally, highly selected sample individuals either eligible A4 study, ineligible owing low amyloid PET signal, may fully represent community-dwelling older adults.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"available-predictors-only-partially-discriminate-future-decline","dir":"Articles","previous_headings":"","what":"Available Predictors Only Partially Discriminate Future Decline","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Although plasma P-tau217 amyloid PET associated latent class membership, neither biomarker alone, combination, achieved high accuracy predicting cognitive decline. key observation high frequency cognitive stability among amyloid-positive participants. shown Table 1, 776 1,110 amyloid-positive A4 participants (69.9%) classified stable individuals, indicating substantial amyloid burden necessarily translate measurable cognitive change timescales typical prevention trials. However, consistent pre-symptomatic phase disease believed last long 15 years. Compared 30.1% amyloid-positive individuals classified decliners, small minority amyloid-negative LEARN participants classified decliners. Thirty-eight 519 (7.3%) amyloid-negative individuals classified slow fast decliners, suggesting causes decline may reflect non–AD processes, early AD pathology PET detection thresholds baseline accumulated 5 year period, cognitive measurement variability. findings reinforce amyloid positivity, necessary defining AD pathophysiologic continuum, insufficient standalone predictor short- intermediate-term cognitive decline.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"relative-contributions-of-plasma-p-tau217-and-tau-pet","dir":"Articles","previous_headings":"","what":"Relative Contributions of Plasma P-tau217 and Tau PET","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Plasma P-tau217 demonstrated stronger prognostic associations amyloid PET, consistent biomarker models positioning tau abnormalities closer symptom onset. observation aligns prior reports, showing improved prognostic accuracy plasma tau markers.5 However, classification tree analyses indicated single P-tau217 threshold meaningfully enriched decliners without simultaneously excluding many true decliners, underscoring limitations threshold-based enrichment strategies. Tau PET provided incremental predictive value beyond plasma P-tau217 amyloid PET, although gains modest. tau PET captures later-stage pathologic changes, results biologically plausible. Nevertheless, logistical financial limitations tau PET constrain feasibility routine screening tool large-scale prevention trials.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"implications-for-secondary-prevention-trial-design","dir":"Articles","previous_headings":"","what":"Implications for Secondary Prevention Trial Design","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Participant Selection. amyloid-positive individuals remain cognitively stable, eligibility based solely amyloid positivity enroll many stable participants, reducing power cognitive endpoints. Plasma P-tau217 may improve enrichment reliably isolate decliners. complex multimodal strategies repeated biomarker assessments may needed adequate prognostic discrimination. Designing Trials Heterogeneous Cohorts. Traditional power calculations assume homogeneous population uniform treatment effect size, overlooking substantial heterogeneity cognitive trajectories. Fast decliners may show larger measurable effects often represent individuals along disease continuum exhibit greater variability, stable individuals pose different challenge. stability limits detectable cognitive benefit even biological effects occur, requiring treatments produce gains beyond natural improvement. analysis shows variability across classes directly influences minimum detectable effect sizes, meaning single-effect-size assumptions risk underpowered studies inefficient resource allocation. realistic simulation-based approaches incorporate class-specific trajectories differential treatment effects can improve trial design informing enrichment strategies, optimizing sample sizes, aligning outcomes subgroup trajectories. Added Value Tau PET. Tau PET provided additional predictive information incremental value must weighed feasibility. Tau-PET-based staging may help identify individuals closer clinical transition, though widespread implementation prevention trials remains challenging. Outcome Selection. Limited cognitive change stable individuals raises questions sensitivity traditional cognitive outcomes early stage. Digital measures learning curves biological endpoints plasma tau PET may offer responsive markers treatment effect serve secondary exploratory outcomes. Given evidence tau PET correlates strongly cognitive decline amyloid biomarkers, longitudinal tau PET plasma P-tau217 may useful monitoring treatment response detecting early trajectory divergence. Future work applying latent class trajectory models biomarker data may clarify whether biomarker-defined progressors can identified earlier reliably cognitive progressors. Early Intervention. Anti-amyloid therapies show greater benefit symptomatic individuals less tau pathology, supporting theory earlier intervention yields greater benefit. However, presymptomatic decline unfolds gradually decade , trials starting early may struggle demonstrate cognitive benefit within feasible windows. Refining validating sensitive digital biomarker-based endpoints essential advancing preclinical therapy development. Reliable measures target engagement disease progression improve enrichment, increase power, enable detection treatment effects even among cognitively stable participants.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"overall-interpretation","dir":"Articles","previous_headings":"","what":"Overall Interpretation","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"summary, data-driven cognitive trajectories among initially unimpaired older adults exhibited substantial heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective predicting decline time frame prevention trial. limitations highlight need improved prognostic tools, potentially incorporating longitudinal biomarker dynamics, multimodal risk models, digital assessments. , secondary prevention trials must account substantial heterogeneity cognitive trajectories planning enrollment, power calculations, trial simulations, analytic strategies.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"strengths-and-limitations","dir":"Articles","previous_headings":"","what":"Strengths and Limitations","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"study several strengths. leveraged large, deeply phenotyped cohort cognitively unimpaired older adults longitudinal cognitive assessments harmonized biomarker data, using A4LEARN R package standardize reproducibly analyze data across A4 LEARN cohorts. latent class mixed-model approach allowed us identify data-driven cognitive trajectories rather relying predefined thresholds single-outcome definitions decline. inclusion plasma P-tau217, amyloid PET, , within subset, tau PET enabled evaluation multiple biomarkers spanning distinct phases Alzheimer disease pathophysiology. study also limitations. First, although latent class methods improve characterization heterogeneity, class assignments probabilistic sensitive model specification. Second, follow-duration, substantial, may still insufficient capture long-term cognitive change among stable individuals. Third, tau PET available subset, limiting statistical power comparisons involving biomarker potentially reducing generalizability. Fourth, although examined broad panel covariates, unmeasured factors, including comorbidities, lifestyle variables, scanner-related differences, may influence biomarker levels cognitive outcomes. Finally, highly selected sample individuals either eligible A4 study, ineligible owing low amyloid PET signal, may fully represent community-dwelling older adults.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"conclusions","dir":"Articles","previous_headings":"","what":"Conclusions","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Among cognitively unimpaired older adults, cognitive trajectories showed marked heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective distinguishing decline. Tau PET provided modest additional predictive value remains impractical widespread enrichment. findings highlight challenge prospectively identifying decliners preclinical Alzheimer’s disease underscore need improved multimodal prognostic tools. Secondary prevention trials account substantial heterogeneity cognitive trajectories developing enrollment strategies, powering cognitive endpoints, interpreting treatment effects.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"acknowledgements","dir":"Articles","previous_headings":"","what":"Acknowledgements","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"authors like thank A4 LEARN Study Teams site principal investigators staff. Special gratitude A4 LEARN participants study partners, without studies possible. Funding: A4 LEARN Studies supported public-private-philanthropic partnership included funding National Institute Aging National Institutes Health (R01 AG063689, U19AG010483 U24AG057437), Eli Lilly (also supplier active medication placebo), Alzheimer’s Association, Accelerating Medicines Partnership Foundation National Institutes Health, GHR Foundation, Davis Alzheimer Prevention Program, Yugilbar Foundation, anonymous foundation, additional private donors Brigham Women’s Hospital, -kind support Avid Radiopharmaceuticals, Cogstate, Albert Einstein College Medicine Foundation Neurologic Diseases. support provided grants Epstein Family Foundation. Conflict Interest Disclosures: Dr Aisen reported personal fees Merck, Biogen, Roche, AbbVie, ImmunoBrain Checkpoint, Bristol Myers Squibb, Neurimmune grants Eisai outside submitted work. Dr Sperling reported consulting fees AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Janssen, Nervgen, Oligomerixg, Prothena, Roche, Vigil Neuroscience, Ionis, Vaxxinity outside submitted work. Dr Donohue reported personal fees Roche (consultant) Janssen Pharmaceuticals (spouse full-time employee) outside submitted work. Dr Raman reported grants American Heart Association, Gates Ventures, Eisai, Alzheimer’s Association. disclosures reported.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"supplementary-material","dir":"Articles","previous_headings":"","what":"Supplementary Material","title":"Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials","text":"Supplementary Figure S1: Association baseline predictors latent class membership longitudinal cognitive decline models without tau PET. Panels B display results latent class mixed model (LCMM) excluding tau PET; panels C D show corresponding results model including tau PET additional predictor. (, C) Odds ratios (95% CIs) LCMM class-membership submodel represent relative likelihood belonging slow- fast-declining classes relative stable class. (B, D) Standardized coefficients (95% CIs) LCMM longitudinal submodel show associations baseline predictors rate change Preclinical Alzheimer Cognitive Composite (PACC). continuous predictors PACC outcome standardized (z-scored) analysis enable comparison effect magnitudes. Higher PACC scores indicate better cognitive performance; thus, larger positive coefficients correspond slower decline better preservation cognition time.  Supplementary Figure S2: Classification tree analysis latent class assignment Base Model. Panel () shows relative importance baseline predictors class separation. Panel (B) shows classification tree showing binary decision rules assigning subjects latent classes based predictors. Terminal nodes show predicted class, number subjects, percentage total sample. optimal tree complexity determined using 10-fold cross-validation 1-standard error rule, resulting tree 6 splits (mean balanced accuracy 0.63, standard error 0.007). Supplementary Table S1: Baseline demographic, clinical, biomarker characteristics latent class cognitive decline tau PET. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit.  Supplementary Figure S3: Individual mean PACC trajectories latent class model tau PET. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM) included tau PET predictor. line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography.  Supplementary Figure S4: Distribution posterior class membership probabilities assigned latent class, indicating model confidence class assignment. plot shows degree certainty class assignments, good indicator model reliability. Mean posterior probabilities 0.95, 0.88, 0.94 non-, slow-, fast decliners. participants high posterior probabilities (>0.8>0.8) assigned class, class separation strong predictive discrimination good.  Supplementary Figure S5: Cross-validated precision-recall curves latent class membership model without tau PET. Precision-recall curves summarizing 10-fold cross-validated classification performance latent class membership submodel based baseline demographics biomarkers, excluding tau PET. Curves depict ability distinguish given class two. area precision-recall curve (AUPRC) quantifies overall predictive performance, emphasizing recall (sensitivity, TP/(TP+FN)) precision (TP/(TP+FP)) less prevalent classes. Abbreviations: AUPRC = area precision-recall curve; TP = true positive rate; FN = false negative rate; FP = false positive rate.  Supplementary Figure S6: Cross-validated precision-recall curves latent class membership model tau PET. Precision-recall curves summarizing 10-fold cross-validated classification performance latent class membership submodel based baseline demographics biomarkers, excluding tau PET. Curves depict ability distinguish given class two. area precision-recall curve (AUPRC) quantifies overall predictive performance, emphasizing recall (sensitivity, TP/(TP+FN)) precision (TP/(TP+FP)) less prevalent classes. Abbreviations: AUPRC = area precision-recall curve; TP = true positive rate; FN = false negative rate; FP = false positive rate.  Supplementary Figure S7: Classification tree analysis latent class assignment Tau PET Model. () Relative importance baseline characteristics class separation. (B) Classification tree showing binary decision rules assigning subjects latent classes based baseline characteristics. Terminal nodes show predicted class, number subjects, percentage total sample. optimal tree complexity determined using 10-fold cross-validation 1-standard error rule, resulting tree 6 splits (mean balanced accuracy 0.69 , standard error 0.02 ). Supplementary Table S2: Power latent class-specific clinical trials. Effect size estimates derived longitudinal models using natural cubic splines (two degrees freedom) applied Preclinical Alzheimer Cognitive Composite (PACC) scores among amyloid-positive A4 participants () stable class (b) two decliner classes. table reports mean PACC residual variance 2 4 years, representing expected control group trajectories two potential trial durations. Power approximated using two-sample t-test calculations assuming 500 participants per group, 10% attrition 2 years 20% 4 years. Effect size expressed absolute PACC change percentage maximum possible improvement, defined mean PACC among stable amyloid-negative LEARN participants corresponding time point.","code":""},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"ATRI Biostatistics. Author, maintainer.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"ATRI Biostatistics (2026). A4LEARN: A4LEARN Study Package. R package version 1.1.20250808, https://www.a4studydata.org.","code":"@Manual{,   title = {A4LEARN: A4LEARN Study Package},   author = {{ATRI Biostatistics}},   year = {2026},   note = {R package version 1.1.20250808},   url = {https://www.a4studydata.org}, }"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"overview","dir":"","previous_headings":"","what":"Overview","title":"A4LEARN Study Package","text":"A4LEARN R package containing data code reproduce results Anti-Amyloid Treatment Asymptomatic Alzheimer’s (A4) study (Sperling et al. 2023) Longitudinal Evaluation Amyloid Risk Neurodegeneration (LEARN) study (Sperling et al. 2024). A4LEARN bundle clinical data, analysis code examples, html pdf documentation. Documentation can found https://atri-biostats.github.io/A4LEARN/. data, including A4LEARN R package, available either: https://www.a4studydata.org/ registering agreeing terms use. https://www.synapse.org/a4_learn_datasharing/ registering account, fulfilling actions ‘Access Actions Required’ tab download cart, adding files download.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"A4LEARN Study Package","text":"install A4LEARN: Register https://www.a4studydata.org/ https://www.synapse.org/a4_learn_datasharing/ Download A4LEARN_1.1.20250808.tar.gz preferred data sharing platform R, run install.packages(\"path//A4LEARN_1.1.20250808.tar.gz\", repos = NULL, type = \"source\") script build R package can found tools.","code":""},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"load-required-r-packages","dir":"","previous_headings":"","what":"Load required R packages","title":"A4LEARN Study Package","text":"","code":"library(tidyverse) library(arsenal) library(kableExtra) library(nlme) library(emmeans) library(splines) library(clubSandwich) library(A4LEARN)  formatp <- function(x) case_when(   x < 0.001 ~ \"p<0.001\",   x > 0.01 ~ Hmisc::format.pval(x, digits=2, eps=0.01, nsmall=2),   TRUE ~ Hmisc::format.pval(x, digits=3, eps=0.001, nsmall=3))"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"organize-data","dir":"","previous_headings":"","what":"Organize data","title":"A4LEARN Study Package","text":"","code":"# Outcomes collected at Visit 1 V1OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"001\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  # Outcomes collected at Visit 6 V6OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"006\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  SUBJINFO <- A4LEARN::SUBJINFO %>%   left_join(V6OUTCOME, by = \"BID\") %>%   left_join(V1OUTCOME %>%       select(BID, CDRSB, CFITOTAL, CFISP, CFIPT, ADLPQPT, ADLPQSP),      by = \"BID\")  # Filter A4LEARN::ADQS for PACC collected in the blinded phases among mITT population ADQS_PACC <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"006\") %>%   dplyr::filter(QSTESTCD == \"PACC\") %>%   rename(PACC = QSSTRESN) %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSVERSION, PACC) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit()"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"baseline-characteristics-of-the-a4-trial","dir":"","previous_headings":"","what":"Baseline characteristics of the A4 trial","title":"A4LEARN Study Package","text":"Characteristics A4 participants randomized treatment group (Modified Intention--Treat Population received least one dose solanezumab placebo underwent assessment primary end point).","code":"A4labels <- list(TX = \"Treatment group\", AGEYR = \"Age (y)\",    EDCCNTU = \"Education (y)\", SUVRCER = \"FBP SUVr\", AMYLCENT = \"FBP Centiloid\",    LMIIa = \"LM Delayed Recall\",  MMSE = \"MMSE\",    CFITOTAL = \"CFI Combined\", ADLPQSP = \"ADL Partner\", CDRSB = \"CDR-SB\",   SEX = \"Sex\", RACE = \"Racial categories\", ETHNIC = \"Ethnicity\",    MARITAL = \"Marital Status\",  WRKRET = \"Retirement Status\",    APOEGNPRSNFLG = \"APOE e4\", APOEGN = \"APOE Genotype\")  table1 <- tableby(TX ~ AGEYR + EDCCNTU + SEX + RACE + ETHNIC + MARITAL + WRKRET +      SUVRCER + AMYLCENT + chisq(APOEGN) + chisq(APOEGNPRSNFLG) +      PACC + LMIIa + MMSE + CFITOTAL + ADLPQSP + CDRSB,    data = SUBJINFO %>% dplyr::filter(MITTFL== 1),    control = tableby.control(test=TRUE,     stats.labels = list(Nmiss = \"Missing\")))  summary(table1, labelTranslations = A4labels, digits = 1,   title = \"Characteristics of the A4 participants by randomized treatment group (Modified Intention-to-Treat Population of those who received at least one dose of solanezumab or placebo and underwent assessment for the primary end point).\")"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"primary-analyis-of-the-pacc","dir":"","previous_headings":"","what":"Primary analyis of the PACC","title":"A4LEARN Study Package","text":"Preclinical Alzheimer Cognitive Composite (PACC, Donohue et al. (2014)) data modeled using natural cubic splines described Donohue et al. (2023). fixed effects included following terms: () spline basis expansion terms (two terms), (ii) spline basis expansion terms--treatment interaction (two terms), (iii) PACC test version administered, (iv) baseline age, (v) education, (vi) APOE4 Carrier Status (yes/), (vii) baseline florbetapir cortical SUVr. model constrained allow difference treatment group means baseline. following variance-covariance structures assumed sequence model converged: () heterogeneous unstructured, (ii) heterogeneous Toeplitz, (iii) heterogeneous autoregressive order 1, (iv) heterogeneous compound symmetry, (v) compound symmetry. first structure, heterogeneous unstructured, converge. fit second, heterogeneous Toeplitz, converge. Spaghetti plot PACC data time treatment group. Mean PACC change baseline week 240 treatment group estimated spline model. Mean PACC group change baseline week 240 treatment group estimated spline model. Mean PACC per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"ggplot(ADQS_PACC, aes(x=ADURW, y=PACC, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.2)) +   xlab(\"Weeks since Randomization\") +   scale_x_continuous(breaks = seq(0, max(ADQS_PACC$ADURW), by = 24)) # Spline basis expansion functions # CAUTION: these function depend on the ADQS_PACC data frame object in the  # global environment. If ADQS_PACC changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: pacc_fit <- gls(PACC ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER + QSVERSION,   data = ADQS_PACC,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 10)) ref_grid(pacc_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(pacc_fit,    at = list(ADURW = 240, TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(pacc_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean PACC with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.2))"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"primary-analyis-of-the-cfi","dir":"","previous_headings":"","what":"Primary analyis of the CFI","title":"A4LEARN Study Package","text":"Spaghetti plot CFI data time treatment group. Mean CFI change baseline week 240 treatment group estimated spline model. Mean CFI group change baseline week 240 treatment group estimated spline model. Mean CFI per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"# Filter A4LEARN::ADQS for CFITOTAL collected in the blinded phases among mITT population ADQS_CFI <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"001\") %>%   dplyr::filter(QSTESTCD == \"CFITOTAL\") %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSSTRESN) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit() ggplot(ADQS_CFI, aes(x=ADURW, y=QSSTRESN, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.9)) +   xlab(\"Weeks since Randomization\") +   ylab(\"CFI Participant and Partner\") scale_x_continuous(breaks = seq(0, max(ADQS_CFI$ADURW), by = 24)) <ScaleContinuousPosition>  Range:    Limits:    0 --    1 # Spline basis expansion functions # CAUTION: these function depend on the ADQS_CFI data frame object in the  # global environment. If ADQS_CFI changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: cfi_fit <- gls(QSSTRESN ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER,   data = ADQS_CFI,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 5)) ref_grid(cfi_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(cfi_fit,    at = list(ADURW = 240, TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(cfi_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean CFI with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.9))"},{"path":[]}]
